Inhibition of the mevalonate pathway augments the activity of pitavastatin against ovarian cancer cells
Abstract Only 40% of patients with advanced ovarian cancer survive more than 5 years. We have previously shown that pitavastatin induces regression of ovarian cancer xenografts in mice. To evaluate whether the response of ovarian cancer cells to pitavastatin is potentiated by farnesyl diphosphate sy...
Main Authors: | Marwan Ibrahim Abdullah, Mohammed Najim Abed, Alan Richardson |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2017-08-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-017-08649-9 |
Similar Items
-
Evaluation of the mevalonate pathway as a target for the treatment of ovarian cancer
by: Abdullah, Marwan Ibrahim
Published: (2018) -
Inhibiting Airway Smooth Muscle Contraction Using Pitavastatin: A Role for the Mevalonate Pathway in Regulating Cytoskeletal Proteins
by: Robin A. Lu, et al.
Published: (2020-05-01) -
Anti-tumor effects of mevalonate pathway inhibition in ovarian cancer
by: Andy Göbel, et al.
Published: (2020-07-01) -
Dietary geranylgeraniol can limit the activity of pitavastatin as a potential treatment for drug-resistant ovarian cancer
by: Elizabeth de Wolf, et al.
Published: (2017-07-01) -
Activity of mevalonate pathway inhibitors against breast and ovarian cancers in the ATP-based tumour chemosensitivity assay
by: Dexel Susanne, et al.
Published: (2009-01-01)